Home
The Infectious Diseases Clinical Research Consortium (IDCRC) and Vaccine and Treatment Evaluation Units (VTEUs) work in tandem with the National Institute of Allergy and Infectious Diseases (NIAID) as a coordinated national and global network of scientific experts working to develop and test vaccines and other therapies to combat infectious diseases.
About
The IDCRC works through a flexible, sustaining structure to advance new countermeasures and approaches to product development, implement efficient clinical study/trial designs, and support exceptional career development and mentoring of future leaders in infectious diseases clinical research. The consortium's collective experience and access to diverse populations give it the ability to evaluate new vaccines and therapies for infectious diseases.
Join us for the 2024 Annual Meeting
Join us on May 1-2, 2024 for our 2024 Annual Meeting. This year's program will highlight the numerous scientific accomplishments of the IDCRC and VTEUs and provide ample networking opportunities for members. Registration information is coming soon!
ANNUAL MEETING WEBPAGECall for Submissions: Annual Meeting Poster Session
The IDCRC invites submissions for the poster session of the 2024 IDCRC Annual Meeting. The Annual Meeting poster session is an excellent opportunity to share research within the IDCRC network in an interactive setting. The meeting program will include time for poster discussion, and there will be dedicated space for posters to remain up for viewing throughout the session. The submission deadline is Friday, March 29.
LEARN MORE & SUBMITCOVID-19 Vaccination and Boosting During Pregnancy Protects Infants for Six Months
Results from the Multisite Observational Maternal and Infant COVID-19 Vaccine (MOMI-Vax) study revealed that when pregnant volunteers received both doses of an mRNA COVID-19 vaccine, antibodies induced by the vaccine could be found in their newborns’ cord blood. This suggested that the infants likely had some protection against COVID-19 when they were still too young to receive a vaccine. Researchers at the NIAID-funded IDCRC, which conducted the study, did not know how long these antibody levels would last or how well the infants would actually be protected. The research team hoped to gather this information by following the infants through their first six months of life.
Read MoreCOVID-19 Prevention Network
The CoVPN was established by merging four existing NIAID-funded clinical trials networks: the HIV Vaccine Trials Network; the HIV Prevention Trials Network; the Infectious Diseases Clinical Research Consortium; and the AIDS Clinical Trials Group.
More about the CoVPNNews from VTEU Trials
IDCRC Leadership Group
IDCRC Concept Quick Stats
ICP Status
- Approved: 56
- Administratively Not Supported: 29
- Not Approved: 51
- EWG Review: 1
- EWG Liaisons: 1
- EMT Concurrence: 0
- Withdrawn: 15
- Hold: 0
- Moved to Active Study: 2
EWG Assignment
- COVID: 92
- Respiratory: 27
- Emerging Infections: 13
- Enteric Infections: 7
- Malaria/Topical Diseases: 13
- STI: 15
ECP
- EWG Review-In Process: 6
- EMT Review: 2
- Approved-moved to Prioritization: 5
- Not Approved: 14
- Approved-moved to Protocol Development: 2
- Active Study: 5
- EMT Vote: 0
- Study in Protocol Development: 6
- Study Closed (LSLV Complete): 5
- Other: 8
IDCRC Citation Statement
Please include the following citation in any publications resulting from direct or indirect IDCRC support:
"Supported by the Infectious Diseases Clinical Research Consortium through the National Institute for Allergy and Infectious Diseases of the National Institutes of Health, under award number UM1AI148684. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health."